Reactivation of Epstein–Barr virus (Herpesviridae: Lymphocryptovirus, HHV-4) infection during COVID-19: epidemiological features
- Authors: Solomay T.V.1,2, Semenenko T.A.3,4, Filatov N.N.2,4, Vedunova S.L.2, Lavrov V.F.2,5, Smirnova D.I.2, Gracheva A.V.2, Faizuloev E.B.2
-
Affiliations:
- Interregional Department No. 1 of the Federal Medical and Biological Agency
- FSBSI «I.I. Mechnikov Research Institute of Vaccines and Sera»
- FSBI «National Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya» of the Ministry of Health of Russia
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- FSBEI FPE «Russian Medical Academy of Continuous Professional Education» of the Ministry of Health of Russia
- Issue: Vol 66, No 2 (2021)
- Pages: 152-161
- Section: ORIGINAL RESEARCH
- URL: https://journals.rcsi.science/0507-4088/article/view/118169
- DOI: https://doi.org/10.36233/0507-4088-40
- ID: 118169
Cite item
Full Text
Abstract
Introduction. Immunodeficiency underlying the development of severe forms of new coronavirus infection may be the result of mixed infection with SARS-CoV-2 and other pathogens, including Epstein–Barr virus (EBV).
The aim is to study the prevalence and epidemiological features of co-infection with SARS-CoV-2 and EBV.
Material and methods. A cross-sectional randomized study was conducted in Moscow region from March to May 2020. Two groups were examined for EBV-markers: hospital patients (n = 95) treated for SARS-CoV-2 infection and blood donors (n = 92).
Results. With equal EBV prevalence the detection of active infection markers in donors (10.9%) was noticeably lower than in SARS-CoV-2 patients (80%). Significant differences in this indicator were also found when patients from subgroups with interstitial pneumonia with the presence (96.6%) and absence (97.2%) of SARS-CoV-2 in the nasopharyngeal smear were compared with the subgroup of patients with mild COVID-19 (43.3%). The average IgG VCA and IgG EBNA positivity coefficients in donor group were higher than in patient group (p < 0.05). Patients with active EBV infection markers were significantly more likely to have pneumonia, exceeding the reference values of ALT and the relative number of monocytes (odds ratio – 23.6; 3.5; 9.7, respectively).
Discussion. The present study examined the incidence and analyzed epidemiological features of active EBV infection in patients with COVID-19.
Conclusion. A significantly higher rate of detection of active EBV infection markers in hospital patients indicates a combined participation SARS-CoV-2 and EBV in the development of interstitial pneumonia. Low levels of specific IgG EBV serve as predictors of EBV reactivation. Exceeding the reference values of ALT and the relative number of monocytes in patients should serve as a reason for examination for active EBV infection markers.
Full Text
##article.viewOnOriginalSite##About the authors
T. V. Solomay
Interregional Department No. 1 of the Federal Medical and Biological Agency; FSBSI «I.I. Mechnikov Research Institute of Vaccines and Sera»
Author for correspondence.
Email: solomay@rambler.ru
ORCID iD: 0000-0002-7040-7653
Solomay Tatyana Valeryevna, PhD (Medicine), Deputy Head of the Interregional Department № 1 of the FMBA of Russia; Senior Researcher, Laboratory of Epidemiological Analysis and Monitoring of Infectious Diseases, Federal State Budgetary Scientific Institution "I. I. Mechnikov Research Institute of Vaccines and Serums", Ministry of Education and Science of the Russian Federation
123182, Moscow
105064, Moscow
T. A. Semenenko
FSBI «National Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya» of the Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: semenenko@gamaleya.org
ORCID iD: 0000-0002-6686-9011
Semenenko Tatyana Anatolyevna, Dr of Sci (Medicine), Professor, Head of the Department of Epidemiology, Federal State Budgetary Institution "National Research Center of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya" of the Ministry of Health of the Russian Federation; Professor of the Department of Infectology and Virology of the I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
123098, Moscow
Moscow, 119991
N. N. Filatov
FSBSI «I.I. Mechnikov Research Institute of Vaccines and Sera»; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: n.n.filatov@yandex.ru
ORCID iD: 0000-0003-4857-9624
Filatov Nikolay Nikolaevich, Dr of Sci (Medicine), Professor, corresponding member of RAS, Deputy Director on scientific work, Federal state budget scientific institution "Scientific research Institute of vaccines and sera them. I. I. Mechnikov" Ministry of education and science, head, Department of epidemiology and modern vaccine technologies, Institute Federal STATE Autonomous educational institution of the First Moscow state medical University named after I. M. Sechenov of Ministry of healthcare of the Russian Federation (sechenovskiy University)
105064, Moscow
Moscow, 119991
S. L. Vedunova
FSBSI «I.I. Mechnikov Research Institute of Vaccines and Sera»
Email: svetl.vedunova2012@yandex.ru
ORCID iD: 0000-0002-8992-9080
Vedunova Svetlana Leonardovna, PhD (Biology), Leading Researcher of the Laboratory for Diagnostics of Viral Infections
105064, Moscow
tel. 89636397205
V. F. Lavrov
FSBSI «I.I. Mechnikov Research Institute of Vaccines and Sera»; FSBEI FPE «Russian Medical Academy of Continuous Professional Education» of the Ministry of Health of Russia
Email: v.f.lavrov@inbox.ru
ORCID iD: 0000-0001-7006-506X
Lavrov Vyacheslav Fedorovich, Dr of Sci (Medicine), Professor, chief researcher, head of laboratory diagnostics of viral infections, Federal state budgetary scientific institution "Scientific research Institute of vaccines and sera them. I. I. Mechnikov" of the Ministry of education of Russia; Professor, Department of epidemiology, FGBOU DPO "Russian medical Academy of continuous education", Ministry of health of Russia
105064, Moscow
125993, Moscow
tel. (495) 916-22-03
D. I. Smirnova
FSBSI «I.I. Mechnikov Research Institute of Vaccines and Sera»
Email: daria.sm.1995@mail.ru
ORCID iD: 0000-0001-7325-0834
Smirnova Darya Ilinichna, Junior Researcher, Laboratory of Molecular Virology
105064, Moscow
Russian FederationA. V. Gracheva
FSBSI «I.I. Mechnikov Research Institute of Vaccines and Sera»
Email: nastuxa_70@mail.ru
ORCID iD: 0000-0001-8428-4482
Gracheva Anastasiia Vyacheslavovna, Junior Researcher, Laboratory of Molecular Virology
105064, Moscow
Russian FederationE. B. Faizuloev
FSBSI «I.I. Mechnikov Research Institute of Vaccines and Sera»
Email: faizuloev@mail.ru
ORCID iD: 0000-0001-7385-5083
Faizuloev Evgeny Bakhtierovich, PhD (Biology), Head of the Laboratory of Molecular Virology
105064, Moscow
Russian FederationReferences
- Salzberger B., Buder F., Lampl B., Ehrenstein B., Hitzenbichler F., Hanses F. Epidemiology of SARS-CoV-2 infection and COVID-19. Internist (Berl). 2020; 61(8): 782–8. https://doi.org/10.1007/s00108-020-00834-9 (in German).
- Акимкин В.Г., Кузин С.Н., Семененко Т.А., Плоскирева А.А., Дубоделов Д.В., Тиванова Е.В., и др. Гендерно-возрастная характеристика пациентов с COVID-19 на разных этапах эпидемии в Москве. Проблемы особо опасных инфекций. 2020; (3): 27–35. https://doi.org/10.21055/0370-1069-2020-3-27-35.
- Акимкин В.Г., Кузин С.Н., Семененко Т.А., Шипулина О.Ю., Яцышина С.Б., Тиванова Е.В., и др. Закономерности эпидемического распространения SARS-CoV-2 в условиях мегаполиса. Вопросы вирусологии. 2020; 65(4): 203–11. https://doi.org/10.36233/0507-4088-2020-65-4-203-211.
- Xiong Y., Sun D., Liu Y., Fan Y., Zhao L., Li X., et al. Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes. Invest. Radiol. 2020; 55(6): 332–9. https://doi.org/10.1097/RLI.0000000000000674.
- Zhao D., Yao F., Wang L., Zheng L., Gao Y., Ye J., et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin. Infect. Dis. 2020; 71(15): 756–61. https://doi.org/10.1093/cid/ciaa247.
- Коган Е.А., Березовский Ю.С., Проценко Д.Д., Багдасарян Т.Р., Грецов Е.М., Демура С.А., и др. Патологическая анатомия инфекции, вызванной SARS-CoV-2. Судебная медицина. 2020; 6(2): 8–30. https://doi.org/10.19048/2411-8729-2020-6-2-8-30.
- Соломай Т.В., Семененко Т.А., Иванова М.Ю. Роль Эпштейна–Барр вирусной инфекции и гепатитов В и С в патологии печени. Вопросы вирусологии. 2019; 64(5): 215–20. https://doi.org/10.36233/0507-4088-2019-64-5-215-220.
- Соломай Т.В., Семененко Т.А. Вирусные гепатиты В, С и инфекционный мононуклеоз: эпидемиологическое сходство и различия. Вопросы вирусологии. 2020; 65(1): 27–34. https://doi.org/10.36233/0507-4088-2020-65-1-27-34.
- Na I.K., Buckland M., Agostini C., Edgar J.D.M., Friman V., Michallet M., et al. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur. J. Haematol. 2019; 102(6): 447–56. https://doi.org/10.1111/ejh.13223.
- Chinen J., Shearer W.T. Secondary immunodeficiencies, including HIV infection. J. Allergy Clin. Immunol. 2010; 125(2 Suppl. 2): 195–203. https://doi.org/10.1016/j.jaci.2009.08.040.
- Харченко Е.П. Коронавирус SARS-Cov-2: сложности патогенеза, поиски вакцин и будущие пандемии. Эпидемиология и Вакцинопрофилактика. 2020; 19(3): 4–20. https://doi.org/10.31631/2073-3046-2020-19-3-4-20.
- Vavougios G.D. Overlapping host pathways between SARS-CoV-2 and its potential copathogens: An in silico analysis. Infect. Genet. Evol. 2020; 86: 104602. https://doi.org/10.1016/j.meegid.2020.104602.
- Nieto-Moro M., Ecclesia F.G., Tomé-Masa I., De Lama Caro-Patón G., Leoz-Gordillo I., Cabrero-Hernández M., et al. SARS-CoV-2 and Streptococcus pneumoniae coinfection as a cause of severe pneumonia in an infant. Pediatr. Pulmonol. 2020; 55(9): 2198–200. https://doi.org/10.1002/ppul.24916.
- Соломай Т.В., Семененко Т.А., Каражас Н.В., Рыбалкина Т.Н., Корниенко М.Н., Бошьян Р.Е., и др. Оценка риска инфицирования герпесвирусами при переливании донорской крови и её компонентов. Анализ риска здоровью. 2020; (2): 135–42. https://doi.org/10.21668/health.risk/2020.2.15.eng.
- Соломай Т.В. Многолетняя динамика заболеваемости и территориальное распространение инфекционного мононуклеоза. Здравоохранение Российской Федерации. 2019; 63(4): 186–92. https://doi.org/10.18821/0044-197X-2019-63-4-186-192.
- Соломай Т.В., Филатов Н.Н. Сезонность инфекции, вызванной вирусом Эпштейна–Барр. Журнал инфектологии. 2020; 12(4): 93–100. https://doi.org/10.22625/2072-6732-2020-12-4-93-100.
- Taylor G.S., Long H.M., Brooks J.M., Rickinson A.B., Hislop A.D. The immunology of Epstein–Barr virus-induced disease. Annu. Rev. Immunol. 2015; 33: 787–821. https://doi.org/10.1146/annurev-immunol-032414-112326.
- Lehner G.F., Klein S.J., Zoller H., Peer A., Bellmann R., Joannidis M. Correlation of interleukin-6 with Epstein–Barr virus levels in COVID-19. Crit. Care. 2020; 24(1): 657. https://doi.org/10.1186/s13054-020-03384-6.
- Pasin F., Mascalchi Calveri M., Calabrese A., Pizzarelli G., Bongiovanni I., Andreoli M., et al. Oncolytic effect of SARS-CoV2 in a patient with NK lymphoma. Acta Biomed. 2020; 91(3): e2020047. https://doi.org/10.23750/abm.v91i3.10141.
- Liya G., Yuguang W., Jian L., Huaiping Y., Xue H., Jianwei H., et al. Studies on viral pneumonia related to novel coronavirus SARSCoV-2, SARS-CoV, and MERS-CoV: a literature review. APMIS. 2020; 128(6): 423–32. https://doi.org/10.1111/apm.13047.
- Guenther J.F., Cameron J.E., Nguyen H.T., Wang Y., Sullivan D.E., Shan B., et al. Modulation of lung inflammation by the Epstein–Barr virus protein Zta. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010; 299(6): L771–84. https://doi.org/10.1152/ajplung.00408.2009.
- Tachikawa R., Tomii K., Seo R., Nagata K., Otsuka K., Nakagawa A., et al. Detection of herpes viruses by multiplex and real-time polymerase chain reaction in bronchoalveolar lavage fluid of patients with acute lung injury or acute respiratory distress syndrome. Respiration. 2014; 87(4): 279–86. https://doi.org/10.1159/000355200.
- Aslan N., Watkin L.B., Gil A., Mishra R., Clark F.G., Welsh R.M., et al. Severity of acute infectious mononucleosis correlates with cross-reactive influenza CD8 T-cell receptor repertoires. mBio. 2017; 8(6): e01841-17. https://doi.org/10.1128/mBio.01841-17.
- He C.-S., Handzlik M., Muhamad A., Gleeson M. Influence of CMV/EBV serostatus on respiratory infection incidence during 4 months of winter training in a student cohort of endurance athletes. Eur. J. Appl. Physiol. 2013; 113(10): 2613–9. https://doi.org/10.1007/s00421-013-2704-x.
- Morand A., Roquelaure B., Colson P., Amrane S., Bosdure E., Raoult D., et al. Child with liver transplant recovers from COVID-19 infection. A case report. Arch. Pediatr. 2020; 27(5): 275–6. https://doi.org/10.1016/j.arcped.2020.05.004.
- García-Martínez F.J., Moreno-Artero E., Jahnke S. SARS-CoV-2 and EBV coinfection. Med. Clin. (Barc.). 2020; 155(7): 319–20. https://doi.org/10.1016/j.medcle.2020.06.010.
- Wang Y., Liu S., Liu H., Li W., Lin F., Jiang L., et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J. Hepatol. 2020; 73(4): 807–16. https://doi.org/10.1016/j.jhep.2020.05.002.
- Zou X., Fang M., Li S., Wu L., Gao B., Gao H., et al. Characteristics of liver function in patients with SARS-CoV-2 and chronic HBV coinfection. Clin. Gastroenterol. Hepatol. 2021; 19(3): 597–603. https://doi.org/10.1016/j.cgh.2020.06.017.
- Ma Y.L., Xia S.Y., Wang M., Zhang S.M., Du W.H., Chen Q. Clinical features of children with SARS-CoV-2 infection: an analysis of 115 cases. Zhongguo Dang Dai Er Ke Za Zhi [Chinese journal of contemporary pediatrics]. 2020; 22(4): 290–3. https://doi.org/10.7499/j.issn.1008-8830.2003016 (in Chinese).
- Anastasiou O.E., Korth J., Herbstreit F., Witzke O., Lange C.M. Mild versus severe liver injury in SARS-CoV-2 infection. Dig. Dis. 2021; 39: 52–7. https://doi.org/10.1159/000510758.
- Ponziani F.R., Del Zompo F., Nesci A., Santopaolo F., Ianiro G., Pompili M., et al. “Gemelli against COVID-19” group. Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients. Aliment. Pharmacol. Ther. 2020; 52(6): 1060–8. https://doi.org/10.1111/apt.15996.
- Gendrot M., Andreani J., Boxberger M., Jardot P., Fonta I., Le Bideau M., et al. Antimalarial drugs inhibit the replication of SARSCoV-2: An in vitro evaluation. Travel Med. Infect. Dis. 2020; 37: 101873. https://doi.org/10.1016/j.tmaid.2020.101873.
- Doyno C., Sobieraj D.M., Baker W.L. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clin. Toxicol. (Phila). 2020; 59(1): 12–23. https://doi.org/10.1080/15563650.2020.1817479.